[{"id":"debiopharm","kind":"company","name":"Debiopharm","route":"/companies/debiopharm/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/companies.ts","type":"changed","fields":[{"field":"tldr","before":"\"Private Swiss developer of the WEE1 inhibitor zedoresertib (Debio 0123) and dual-payload ADC research.\"","after":"\"Debiopharm is the private Swiss developer of the WEE1 inhibitor zedoresertib (Debio 0123) and of dual-payload ADC research.\""}]},{"id":"debiopharm","kind":"company","name":"Debiopharm","route":"/companies/debiopharm/","commit":"335b83f6e7","date":"2026-09-06","author":"Jude Gomila","message":"Expand companies: Katsutake map imports and 44 frontier oncology companies; add frontier technologies (programmable DNA-targeting, fragmento","file":"src/data/companies.ts","type":"added","fields":[{"field":"id"},{"field":"name"},{"field":"hq"},{"field":"country"},{"field":"companyType"},{"field":"website"},{"field":"sections"},{"field":"tldr"},{"field":"summary"},{"field":"targets"},{"field":"technologies"},{"field":"cancers"},{"field":"links"}]}]